Iteos Therapeutics Taps Sarepta’s Gall as Chief Financial Officer

Cancer drug developer Iteos Therapeutics announced Tuesday that it appointed Matthew Gall as its chief financial officer. Gall was most recently senior vice president of corporate development and treasurer at Sarepta Therapeutics (NASDAQ: [[ticker:SRPT]]). His previous experience includes roles at Celgene and Gilead Sciences (NASDAQ: [[ticker:GILD]]).

Iteos, a Belgium-based firm with US headquarters in Cambridge, MA, raised $125 million in April to advance its pipeline of cancer treatments, including two clinical-stage programs designed to target mechanisms it believes aid in the suppression of an anti-tumor immune response in the tumor microenvironment.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine. View all posts by Sarah de Crescenzo